Loading live market data…

Lineage, Inc.

NASDAQ:LINE

$44.3936 USD

$0.39 (0.89%)

Volume
728.96K
Average Volume
1.02M
Market Capitalization
$10.11B
P/E Ratio
-71.61
Dividend Yield
4.78%
Price Target
$45.00
Year High
$45.75
Year Low
$31.33
Day High
Day Low
Payout Ratio
$-3.67
Current Ratio
$0.85
Source Headline
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan

Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease.

marketbeat.com - 2026-07-14 03:02:24

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today provided an update on COR1, the Company's allogeneic corneal endothelial cell (CEnC) transplant program, in preclinical development for the treatment of corneal endothelial disease. With COR1, Lineage is deploying its ophthalmology and cell manufacturing expert.

businesswire.com - 2026-07-13 08:00:00

Lineage: Don't Mistake A Cyclical Slump For A Broken Business

Lineage remains a Buy, offering a margin of safety and re-rating potential despite near-term macro and operational headwinds. Q1 saw AFFO per share decline 9.3% to $0.78, but guidance for Adj. EBITDA ($1.25–$1.3B) and AFFO per share ($2.75–$3.00) were maintained. LINE's cost reduction plan and automation investments target $110M annualized EBITDA improvement in 3–5 years, supporting long-term upside.

seekingalpha.com - 2026-07-09 07:01:55

Grand Design RV Unveils the All-New Lineage Series E, Redefining Innovation in Motorized RV Travel

MIDDLEBURY, Ind., July 08, 2026 (GLOBE NEWSWIRE) -- Grand Design RV, the fast-growing innovator of travel trailers, 5th wheels and motorized RVs, today announced the launch of the all-new Lineage series E, expanding its award-winning motorized portfolio with a new Class C motorhome designed to deliver premium comfort, practical functionality and confidence on the road. Built on the dependable Ford® E-450 chassis, the Series E brings Grand Design's owner-focused approach to one of the most established and accessible segments of the motorized RV market.

globenewswire.com - 2026-07-08 09:59:00

Linear Provides Update on Proposed Acquisition of Critical Prospecting Corp

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / July 7, 2026 / Linear Minerals Corp. (CSE:LINE)(OTCID:LINMF) (WKN:A40Y3E) ("Linear" or the "Company") is pleased to provide an update on its previously announced letter of intent (the "LOI") to acquire all of the issued and outstanding securities of Critical Prospecting Corp. initially announced in the Company's news release dated May 21, 2026. The Company confirms that it continues to work towards completing the proposed acquisition of certain mineral properties (the "Properties") from Critical Prospecting Corp. (the "Vendor").

accessnewswire.com - 2026-07-07 21:25:00

Lineage to Report Second-Quarter 2026 Financial Results on August 5, 2026

NOVI, Mich.--(BUSINESS WIRE)--Lineage, Inc. (NASDAQ: LINE), announced that it will report its financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before market open. A conference call to discuss these results has been scheduled for 8:00 a.m. Eastern Time on Wednesday, August 5, 2026. A live webcast of the call will be available on the Lineage Investor Relations website at ir.onelineage.com. An audio replay of the conference call will be available for one week followin.

businesswire.com - 2026-07-07 16:15:00

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research an.

businesswire.com - 2026-07-06 08:00:00

Lineage vs. Rexford Industrial Realty: Which Real Estate Stock Is a Better Buy in 2026?

Lineage operates a massive temperature-controlled logistics network across three continents. Rexford Industrial Realty maintains a high-density portfolio focused exclusively on Southern California.

fool.com - 2026-06-26 07:17:01

Lineage: Another Serious Fire Could Spell Trouble

Lineage Logistics faces significant operational and financial risks after two catastrophic fires at major cold storage facilities. Recent fires have led to lawsuits, public health concerns, and potential long-term brand damage, particularly in Los Angeles. Immediate costs include emergency relief and remediation, while longer-term impacts may include higher insurance premiums and increased operating expenses.

seekingalpha.com - 2026-06-25 03:35:33

PREFORMED LINE PRODUCTS ANNOUNCES QUARTERLY DIVIDEND

CLEVELAND, June 18, 2026 /PRNewswire/ -- The Board of Directors of Preformed Line Products (Nasdaq: PLPC) on June 6, 2026, declared a regular quarterly dividend in the amount of $0.21 per share on the Company's common shares, payable July 20, 2026, to shareholders of record at the close of business on July 1, 2026. ABOUT PLP PLP protects the world's most critical connections by creating stronger and more reliable networks.

prnewswire.com - 2026-06-18 16:15:00

LAIRD SUPERFOOD® EXPANDS PRODUCT LINE AT TARGET TO INCLUDE FUNCTIONAL MUSHROOM COFFEES

Nationwide Target Distribution Gives Consumers Access to Both PERFORM and DEFEND Functional Mushroom Coffees for Improved Mental Clarity and Sustained Energy BOULDER, Colo., June 17, 2026 /PRNewswire/ -- Laird Superfood, Inc. (NYSE American: LSF), a leader in functional coffee, creamers, and superfood products made with simple, minimally processed ingredients, has expanded its offerings at Target stores nationwide to include Organic PERFORM Functional Mushroom Coffee and DEFEND Functional Mushroom Coffee.

prnewswire.com - 2026-06-17 09:00:00

Lineage, Inc. Declares Dividend for Second-Quarter 2026

NOVI, Mich.--(BUSINESS WIRE)--Lineage, Inc. (NASDAQ: LINE) (the "Company"), the world's largest global temperature-controlled warehouse REIT, today announced that its Board of Directors has declared a cash dividend of $0.5325 per share for the second quarter of 2026. The dividend will be paid on July 21, 2026, to shareholders of record of the Company's common stock as of the close of business on June 30, 2026. About Lineage Lineage, Inc. (NASDAQ: LINE) is the world's largest global temperature-.

businesswire.com - 2026-06-12 16:15:00

Kuehn Law Encourages Investors of Lineage, Inc. to Contact Law Firm

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Lineage, Inc. (NASDAQ: LINE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Lineage caused the company to misrepresent or fail to disclose that Lineage's financial and operational results had been temporarily inflated leading up to the IPO as a result of artificial market distortions caused by the COVID-19 pandemic, increased supply of cold-storage facilities, and the imposition of unsustainable price increases by Lineage.

globenewswire.com - 2026-06-01 10:57:49

Kuehn Law Encourages Investors of Lineage, Inc. to Contact Law Firm

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  Lineage, Inc. (NASDAQ: LINE) breached their fiduciary duties to shareholders.

globenewswire.com - 2026-06-01 10:57:00

Anti-AI Investing: The HALO Moat

I focus on HALO investing: Heavy Assets, Low Obsolescence - owning irreplaceable physical assets with durable moats against technological disruption. Top recommendations include American Tower, Brookfield Infrastructure, Prologis, Rexford Industrial, Lineage, Americold, VICI Properties, and Lamar Advertising. AMT, COLD, and VICI currently offer attractive entry points based on discounted multiples, robust dividend yields, and resilient, monopoly-like asset bases.

seekingalpha.com - 2026-05-31 08:00:00

Linear Announces Acquisition, Share Consolidation and Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / May 21, 2026 / Linear Minerals Corp. (CSE:LINE)(OTC:LINMF)(WKN:A40Y3E) ("Linear" or the "Company") is pleased to announce that it has entered into a letter of intent (the "LOI") outlining its intention to acquire (the "Transaction") the Mooney Lake Uranium Project, the Hatsoff Tungsten-Molybdenum Project and the Gorge Lithium Project (collectively, the "Properties") via the acquisition of all of the issued and outstanding shares of Critical Prospecting Corp. ("Critical Prospecting"), the current owner of the Properties. Under the terms of the LOI, Linear will acquire all of the issued and outstanding securities of Critical Prospecting in exchange for the issuance of 4,788,000 Post-Consolidation Shares (as defined below) at a price of $0.25 per Post-Consolidation Share for a total purchase price of $1,197,000.

accessnewswire.com - 2026-05-21 16:15:00

Lineage Cell Therapeutics Q1 Earnings Call Highlights

Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing manufacturing initiatives built around its AlloSCOPE platform.

marketbeat.com - 2026-05-15 19:11:39

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today reported its first quarter 2026 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “This quarter, we continued to build on our developmental and clinical acc.

businesswire.com - 2026-05-12 16:01:00

Zouga & Wolf Defines a New Standard for Private Tailoring in the Era of Lineage Luxury

Traditional outfitting regains relevance as Zouga & Wolf elevates private tailoring within a modern framework of lineage luxury and discretion. Traditional outfitting regains relevance as Zouga & Wolf elevates private tailoring within a modern framework of lineage luxury and discretion.

globenewswire.com - 2026-05-11 13:29:00

Lineage: Robots Could Add $30 Per Share

Lineage, the largest cold storage REIT, currently trades at 25% above recent lows, but 50% below the 2024 IPO price. With 24,000 employees, headcount intensity is 20-100x that of typical industrial REITs. Adoption of humanoid robots as the next step in LINE's automation strategy could dramatically reduce headcount and improve financial results.

seekingalpha.com - 2026-05-11 09:05:30

Lineage, Inc. (LINE) Q1 2026 Earnings Call Transcript

Lineage, Inc. (LINE) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 13:01:21

Lineage, Inc. (LINE) Q1 FFO Beat Estimates

Lineage, Inc. (LINE) came out with quarterly funds from operations (FFO) of $0.78 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to FFO of $0.86 per share a year ago.

zacks.com - 2026-05-06 08:26:11

Lineage, Inc. Reports First-Quarter 2026 Financial Results

NOVI, Mich.--(BUSINESS WIRE)--Lineage, Inc. (NASDAQ: LINE) (the "Company"), the world's largest global temperature-controlled warehouse REIT, today announced its financial results for the first quarter of 2026. First-Quarter 2026 Financial Highlights Total revenue increased 0.4% to $1,297 million GAAP net loss of $(51) million, or $(0.18) per diluted common share Adjusted EBITDA increased 3.3% to $314 million; adjusted EBITDA margin increased 70bps to 24.2% AFFO decreased (8.2)% to $201 million.

businesswire.com - 2026-05-06 06:00:00

SPECTRUM MOBILE SECOND LINE LETS CUSTOMERS DITCH THE EXTRA PHONE FOR GOOD

Key Takeaways Spectrum Mobile Second Line allows customers to add a dedicated voice and text number to compatible smartphones for $10 per month. Customers can keep personal and professional communications separate, with no need for a second device or extra apps.

prnewswire.com - 2026-05-05 10:00:00

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eas.

businesswire.com - 2026-05-05 08:00:00

PREFORMED LINE PRODUCTS ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS

CLEVELAND, April 29, 2026 /PRNewswire/ -- Preformed Line Products Company (NASDAQ: PLPC) today reported financial results for its first quarter of 2026. Q1 2026 highlights: Quarterly net sales of $176.3 million, an increase of 19% from Q1 2025.

prnewswire.com - 2026-04-29 16:15:00

Kuehn Law Encourages Investors of Lineage, Inc. to Contact Law Firm

NEW YORK, April 20, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Lineage, Inc. (NASDAQ: LINE) breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Lineage caused the company to misrepresent or fail to disclose that Lineage's financial and operational results had been temporarily inflated leading up to the IPO as a result of artificial market distortions caused by the COVID-19 pandemic, increased supply of cold-storage facilities, and the imposition of unsustainable price increases by Lineage.

prnewswire.com - 2026-04-20 08:26:00

Get LINE Insider Trade Alerts

LINE Price Target Summary

Last Month

$45.50

2 analysts

Last Quarter

$41.71

7 analysts

Last Year

$41.50

22 analysts

All Time

$56.26

35 analysts

LINE Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-07-01 Evercore ISI Group Maintain In Line In Line
2026-06-17 Truist Securities Maintain Buy Buy
2026-06-02 Morgan Stanley Maintain Equal Weight Equal Weight
2026-06-01 Wells Fargo Maintain Equal Weight Equal Weight
2026-05-15 Barclays Maintain Underweight Underweight
2026-05-07 Evercore ISI Group Maintain In Line In Line
2026-04-27 Barclays Downgrade Equal Weight Underweight
2026-04-06 Evercore ISI Group Maintain In Line In Line
2026-04-01 Piper Sandler Maintain Neutral Neutral
2026-03-20 Goldman Sachs Maintain Buy Buy
2026-03-11 Scotiabank Maintain Sector Perform Sector Perform
2026-03-04 Truist Securities Maintain Buy Buy
2026-03-02 Citigroup Maintain Neutral Neutral
2026-03-02 RBC Capital Maintain Outperform Outperform
2026-03-02 Wells Fargo Maintain Equal Weight Equal Weight
2026-02-27 Piper Sandler Maintain Neutral Neutral
2026-02-26 Evercore ISI Group Maintain In Line In Line
2026-01-13 Barclays Downgrade Overweight Equal Weight
2026-01-09 Scotiabank Maintain Sector Perform Sector Perform
2026-01-08 UBS Maintain Neutral Neutral
2025-12-18 Baird Downgrade Outperform Neutral
2025-12-17 Morgan Stanley Maintain Equal Weight Equal Weight
2025-12-04 Citigroup Maintain Neutral Neutral
2025-11-25 Goldman Sachs Maintain Buy Buy
2025-11-25 Wells Fargo Maintain Equal Weight Equal Weight
2025-11-14 JP Morgan Maintain Underweight Underweight
2025-11-12 Scotiabank Maintain Sector Perform Sector Perform
2025-11-12 RBC Capital Maintain Outperform Outperform
2025-11-10 Evercore ISI Group Maintain In Line In Line
2025-11-06 Piper Sandler Downgrade Overweight Neutral
2025-11-06 Mizuho Maintain Neutral Neutral
2025-10-22 Barclays Maintain Overweight Overweight
2025-10-14 UBS Maintain Neutral Neutral
2025-10-06 Evercore ISI Group Maintain In Line In Line
2025-09-23 JP Morgan Maintain Underweight Underweight
2025-09-22 Morgan Stanley Maintain Equal Weight Equal Weight
2025-09-15 Evercore ISI Group Maintain In Line In Line
2025-09-15 Barclays Maintain Overweight Overweight
2025-09-08 Evercore ISI Group Maintain In Line In Line
2025-09-05 Scotiabank Maintain Sector Perform Sector Perform
2025-08-27 Wells Fargo Maintain Equal Weight Equal Weight
2025-08-22 Truist Securities Maintain Buy Buy
2025-08-18 RBC Capital Maintain Outperform Outperform
2025-08-13 Baird Maintain Outperform Outperform
2025-08-12 Goldman Sachs Maintain Buy Buy
2025-08-11 B of A Securities Downgrade Neutral Underperform
2025-08-08 Evercore ISI Group Maintain In Line In Line
2025-08-07 Piper Sandler Maintain Overweight Overweight
2025-08-06 Truist Securities Maintain Buy Buy
2025-07-23 UBS Maintain Neutral Neutral
2025-07-21 Barclays Maintain Overweight Overweight
2025-07-01 Keybanc Downgrade Overweight Sector Weight
2025-06-23 JP Morgan Downgrade Neutral Underweight
2025-06-23 Morgan Stanley Downgrade Overweight Equal Weight
2025-06-18 Goldman Sachs Maintain Buy Buy
2025-06-12 Citigroup Maintain Neutral Neutral
2025-05-19 Wells Fargo Maintain Equal Weight Equal Weight
2025-05-15 Scotiabank Maintain Sector Perform Sector Perform
2025-05-14 Goldman Sachs Maintain Buy Buy
2025-05-05 Piper Sandler Maintain Overweight Overweight
2025-05-02 UBS Maintain Neutral Neutral
2025-05-01 Evercore ISI Group Maintain In Line In Line
2025-05-01 Baird Maintain Outperform Outperform
2025-04-10 Scotiabank Downgrade Sector Outperform Sector Perform
2025-04-01 Morgan Stanley Maintain Overweight Overweight
2025-03-20 Wells Fargo Maintain Equal Weight Equal Weight
2025-03-10 Scotiabank Maintain Sector Outperform Sector Outperform
2025-03-06 RBC Capital Maintain Outperform Outperform
2025-02-27 Piper Sandler Maintain Overweight Overweight
2025-02-27 Baird Maintain Outperform Outperform
2025-02-03 Scotiabank Maintain Sector Outperform Sector Outperform
2025-01-17 Goldman Sachs Maintain Buy Buy
2025-01-08 Mizuho Maintain Neutral Neutral
2024-12-20 JP Morgan Downgrade Overweight Neutral
2024-12-10 Scotiabank Maintain Sector Outperform Sector Outperform
2024-11-14 Goldman Sachs Maintain Buy Buy
2024-11-13 RBC Capital Maintain Outperform Outperform
2024-11-07 Evercore ISI Group Maintain In Line In Line
2024-11-07 Baird Maintain Outperform Outperform
2024-10-07 Evercore ISI Group Maintain In Line In Line
2024-09-13 Goldman Sachs Maintain Buy Buy
2024-09-03 RBC Capital Maintain Outperform Outperform
2024-08-28 Wells Fargo Maintain Equal Weight Equal Weight
2024-08-28 Evercore ISI Group Maintain In Line In Line
2024-08-26 Scotiabank Maintain Sector Outperform Sector Outperform